ArticleScientific reports2026
Integrative multi-omics analysis identified FUT9 and MS4A3 as novel immune-phenotype and prognosis biomarkers for colorectal cancer and analyze the role of FUT9 in oncoimmunology.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide. Patients with different immunophenotypes of CRC could achieve different effect of immunotherapy and yield different prognosis. With the advancement of bioinformatics, multi-omics analysis of the variations at both genomics and epigenomics levels helps a lot to provide a molecular basis for immunophenotype. Gene expression and clinical data of CRC patients were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). We calculated Spearman correlation of CD274 (programmed cell death ligand-1, PD-L1) and IFNG (interferon gamma, IFN-γ) expressions with immune cell fraction, and screened different immune cell types with CD274 and IFNG by Lasso regression analysis. Multi-omics analysis was exploited to screen out candidate genes with differential in genetic and epigenetic landscapes between two CRC subtypes with the greatest difference in immune infiltration. Finally, a risk scoring model was established and the role of candidate genes in prognosis and oncoimmunology was evaluated at the pan-cancer level. Two CRC types (cluster A and cluster B) including five subtypes (subclusters A1, A2, B1, B2A, and B2B) were identified by unsupervised clustering analysis. Somatic mutations, CNVs, and DNA methylation differed between subcluster A2 and B2, and analysis of DEGs correlated with CRC immune phenotypes identified FUT9 and MS4A3 as key genes related to CRC immune-phenotypes and prognosis. Furthermore, FUT9 was validated to act as a key gene related to CRC immune escape in vitro. The present study established a risk model for CRC immunophenotyping and prognosis, and highlighted the significance of FUT9 and MS4A3 in oncoimmunology of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.